Literature DB >> 18257782

Misleading terms in Anderson-Fabry disease.

F Weidemann1, J M Strotmann, F Breunig, M Niemann, R Maag, R Baron, A O Eggert, C Wanner.   

Abstract

BACKGROUND: Signs and symptoms of classic Fabry disease manifest itself on the skin (angiokeratoma), the nervous system (acroparaesthesia), the heart (restrictive cardiomyopathy) and a variety of other organs.
MATERIALS AND METHODS: Diagnosis of Fabry disease was confirmed by genetic tests in a cohort of 100 patients and a standardized examination programme was performed in all patients. We were puzzled when applying well-established and textbook-anchored signs and symptoms to our patients.
RESULTS: Among the 47 male and 53 female patients (mean age 41 +/- 16 years) with genetically proven disease, the Fabry-type vascular skin lesions were without hyperkeratotic aspect and keratomas were virtually absent. The peripheral neuropathic pain found in all male patients was not compatible with the wording 'acro' and 'paraesthesia', suggesting a different pathophysiological mechanism. Upon echocardiographic examination, patients mainly revealed diastolic relaxation abnormalities of the heart and only one patient had a restrictive cardiac pattern.
CONCLUSIONS: Our findings suggest that some terms used to describe signs and symptoms of Fabry disease are historically derived and do not comply with state-of-the-art examination. We propose to replace the term 'angiokeratoma' with 'angioma', the term 'acroparaesthesia' with 'neuropathic pain' and the term 'restrictive cardiomyopathy' with 'cardiac hypertrophic storage disease'. As most of the physicians are not familiar with Fabry disease, terms used in the past might prevent the correct diagnosis of a potentially treatable disease.

Entities:  

Mesh:

Year:  2008        PMID: 18257782     DOI: 10.1111/j.1365-2362.2008.01921.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  6 in total

Review 1.  [The various forms of left ventricular hypertrophy: diagnostic value of echocardiography].

Authors:  F Weidemann; S Störk; S Herrmann; G Ertl; M Niemann
Journal:  Herz       Date:  2011-12       Impact factor: 1.443

Review 2.  [Pain therapy for Fabry's disease].

Authors:  C Sommer; N Uçeyler; T Duning; K Arning; R Baron; E Brand; S Canaan-Kühl; M Hilz; D Naleschinski; C Wanner; F Weidemann
Journal:  Internist (Berl)       Date:  2013-01       Impact factor: 0.743

3.  Persistent increase in cardiac troponin I in Fabry disease: a case report.

Authors:  Christian Tanislav; Andreas Feustel; Wolfgang Franzen; Oliver Wüsten; Christian Schneider; Frank Reichenberger; Arndt Rolfs; Nicole Sieweke
Journal:  BMC Cardiovasc Disord       Date:  2011-01-31       Impact factor: 2.298

Review 4.  Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel.

Authors:  Alessandro P Burlina; Katherine B Sims; Juan M Politei; Gary J Bennett; Ralf Baron; Claudia Sommer; Anette Torvin Møller; Max J Hilz
Journal:  BMC Neurol       Date:  2011-05-27       Impact factor: 2.474

Review 5.  Multimodality Imaging in Cardiomyopathies with Hypertrophic Phenotypes.

Authors:  Emanuele Monda; Giuseppe Palmiero; Michele Lioncino; Marta Rubino; Annapaola Cirillo; Adelaide Fusco; Martina Caiazza; Federica Verrillo; Gaetano Diana; Alfredo Mauriello; Michele Iavarone; Maria Angela Losi; Maria Luisa De Rimini; Santo Dellegrottaglie; Antonello D'Andrea; Eduardo Bossone; Giuseppe Pacileo; Giuseppe Limongelli
Journal:  J Clin Med       Date:  2022-02-07       Impact factor: 4.964

6.  Continuous cardiac troponin I release in Fabry disease.

Authors:  Andreas Feustel; Andreas Hahn; Christian Schneider; Nicole Sieweke; Wolfgang Franzen; Dursun Gündüz; Arndt Rolfs; Christian Tanislav
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.